Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.

Shariati, Maryam; Evans, Kurt W; Zheng, Xiaofeng; Bristow, Christopher A; Ng, Patrick Kwok-Shing; Rizvi, Yasmeen Q; Tapia, Coya; Yang, Fei; Carugo, Alessandro; Heffernan, Timothy P; Peoples, Michael D; Tripathy, Debu; Meric-Bernstam, Funda

Shariati, Maryam; Evans, Kurt W; Zheng, Xiaofeng; Bristow, Christopher A; Ng, Patrick Kwok-Shing; Rizvi, Yasmeen Q; Tapia, Coya; Yang, Fei; Carugo, Alessandro; Heffernan, Timothy P; Peoples, Michael D; Tripathy, Debu; Meric-Bernstam, Funda.

Afiliação

Shariati M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zheng X; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bristow CA; Center for Co-Clinical Trials and Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ng PK; The Sheikh Khalifa Bin Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rizvi YQ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tapia C; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yang F; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carugo A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Heffernan TP; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peoples MD; Center for Co-Clinical Trials and Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tripathy D; Center for Co-Clinical Trials and Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Meric-Bernstam F; Center for Co-Clinical Trials and Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Oncogene ; 40(26): 4425-4439, 2021 07.

Article em En | MEDLINE | ID: mdl-34108622

Assuntos

Neoplasias da Mama/genética; Classe I de Fosfatidilinositol 3-Quinases/genética; Quinases Ciclina-Dependentes/antagonistas & inibidores; Receptor com Domínio Discoidina 1/antagonistas & inibidores; Proteínas Proto-Oncogênicas c-akt/genética; Receptor ErbB-2/genética; Receptores de Estrogênio/genética; Animais; Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia; Neoplasias da Mama/tratamento farmacológico; Pontos de Checagem do Ciclo Celular/efeitos dos fármacos; Pontos de Checagem do Ciclo Celular/genética; Linhagem Celular Tumoral; Proliferação de Células/efeitos dos fármacos; Proliferação de Células/genética; Feminino; Humanos; Células MCF-7; Mutação/genética; Inibidores de Proteínas Quinases/farmacologia; Transdução de Sinais/efeitos dos fármacos; Transdução de Sinais/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio / Receptor ErbB-2 / Quinases Ciclina-Dependentes / Proteínas Proto-Oncogênicas c-akt / Classe I de Fosfatidilinositol 3-Quinases / Receptor com Domínio Discoidina 1 Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google